Merck & Company Inc (MRK)vsSolventum Corp. (SOLV)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
SOLV
Solventum Corp.
$81.01
-1.71%
HEALTHCARE · Cap: $14.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 696% more annual revenue ($65.77B vs $8.26B). SOLV leads profitability with a 17.3% profit margin vs 13.6%. SOLV appears more attractively valued with a PEG of 1.22. SOLV earns a higher WallStSmart Score of 60/100 (C).
MRK
Hold50
out of 100
Grade: D+
SOLV
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for SOLV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 29 in profit
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Revenue declined 3.0%
Earnings declined 91.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SOLV
The strongest argument for SOLV centers on P/E Ratio, Return on Equity, Price/Book. Profitability is solid with margins at 17.3% and operating margin at 5.6%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SOLV
The primary concerns for SOLV are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while SOLV is a declining play — different risk/reward profiles.
SOLV carries more volatility with a beta of 0.75 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SOLV scores higher overall (60/100 vs 50/100), backed by strong 17.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Solventum Corp.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?